Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 2
1955 1
1956 2
1960 1
1966 1
1967 1
1968 1
1969 1
1970 1
1973 1
1975 1
1980 2
1982 3
1983 1
1984 2
1985 2
1986 1
1987 2
1988 4
1990 3
1991 2
1992 1
1993 3
1994 6
1995 5
1996 8
1997 2
1998 8
1999 7
2000 6
2001 11
2002 12
2003 19
2004 13
2005 16
2006 17
2007 17
2008 13
2009 20
2010 26
2011 16
2012 24
2013 20
2014 20
2015 18
2016 23
2017 32
2018 23
2019 25
2020 20
2021 33
2022 13
Text availability
Article attribute
Article type
Publication date

Search Results

455 results
Results by year
Filters applied: . Clear all
Page 1
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Torres VE, et al. Among authors: blais jd. N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4. N Engl J Med. 2017. PMID: 29105594 Free article. Clinical Trial.
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Blais J, Li Q, Jardine MJ, Perkovic V, Wheeler DC. Neuen BL, et al. Among authors: blais j. Am J Kidney Dis. 2021 Jan;77(1):23-34.e1. doi: 10.1053/j.ajkd.2020.06.018. Epub 2020 Sep 21. Am J Kidney Dis. 2021. PMID: 32971190 Clinical Trial.
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators. Torres VE, et al. Among authors: blais jd. Nephrol Dial Transplant. 2018 Mar 1;33(3):477-489. doi: 10.1093/ndt/gfx043. Nephrol Dial Transplant. 2018. PMID: 28379536 Free PMC article. Clinical Trial.
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. Among authors: blais jd. Clin J Am Soc Nephrol. 2016 May 6;11(5):803-11. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23. Clin J Am Soc Nephrol. 2016. PMID: 26912543 Free PMC article. Clinical Trial.
Response to Liu et al., and Björnsson and Björnsson.
Zhao J, Blais JE, Seto WK, Wong ICK, Chan EW. Zhao J, et al. Among authors: blais je. Am J Gastroenterol. 2021 May 1;116(5):1091-1092. doi: 10.14309/ajg.0000000000001055. Am J Gastroenterol. 2021. PMID: 33229977 No abstract available.
Trends in lipid-modifying agent use in 83 countries.
Blais JE, Wei Y, Yap KKW, Alwafi H, Ma TT, Brauer R, Lau WCY, Man KKC, Siu CW, Tan KCB, Wong ICK, Wei L, Chan EW. Blais JE, et al. Atherosclerosis. 2021 Jul;328:44-51. doi: 10.1016/j.atherosclerosis.2021.05.016. Epub 2021 May 27. Atherosclerosis. 2021. PMID: 34091069 Free article.
Legacy organochlorine pollutants in glacial watersheds: a review.
Miner KR, Blais J, Bogdal C, Villa S, Schwikowski M, Pavlova P, Steinlin C, Gerbi C, Kreutz KJ. Miner KR, et al. Among authors: blais j. Environ Sci Process Impacts. 2017 Dec 13;19(12):1474-1483. doi: 10.1039/c7em00393e. Environ Sci Process Impacts. 2017. PMID: 29140398 Review.
455 results